Keros Therapeutics, Inc. (KROS) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$30.94M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$25.88M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$15.38M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$39.82M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$30.94M | (m) | $0.00 | (m) | $155.00K* | -$20.42M* | (m) | $22.33M | (m) | $0.00 |
| 2026-03-31 | Reported | (m) | -$25.88M | (m) | $367.00K | (m) | $73.00K | -$3.53M | (m) | $16.10M | (m) | $0.00 |
| 2025-09-30 | Reported | (m) | -$15.38M | (m) | $14.26M | (m) | $132.00K* | $3.25M* | (m) | $19.52M | (m) | -$1.42M |
| 2025-06-30 | Reported | (m) | -$39.82M | (m) | $18.17M | (m) | $720.00K* | -$29.62M* | (m) | $43.50M | (m) | -$2.22M |
| 2025-03-31 | Reported | (m) | $152.04M | (m) | $211.25M | (m) | $565.00K | $161.17M | (m) | $48.71M | (m) | $10.04M |
| 2024-09-30 | Reported | (m) | -$58.66M | (m) | $388.00K | (m) | $386.00K* | -$30.50M* | (m) | $49.23M | (m) | $0.00 |
| 2024-06-30 | Reported | (m) | -$50.44M | (m) | $37.00K | (m) | $310.00K* | -$39.80M* | (m) | $40.52M | (m) | $0.00 |
| 2024-03-31 | Reported | (m) | -$48.48M | (m) | $83.00K | (m) | $946.00K | -$44.56M | (m) | $38.26M | (m) | $0.00 |
| 2023-09-30 | Reported | (m) | -$43.28M | (m) | $8.00K | (m) | $550.00K* | -$33.98M* | (m) | $34.14M | (m) | (m) |
| 2023-06-30 | Reported | (m) | -$41.34M | (m) | $0.00 | (m) | $311.00K* | -$30.83M* | (m) | $32.53M | (m) | (m) |
| 2023-03-31 | Reported | (m) | -$38.87M | (m) | $0.00 | (m) | $1.06M | -$34.23M | (m) | $31.09M | (m) | (m) |
| 2022-09-30 | Reported | (m) | -$27.98M | (m) | $0.00 | (m) | $176.00K* | -$24.60M* | (m) | $21.04M | (m) | $0.00 |
| 2022-06-30 | Reported | (m) | -$30.73M | (m) | $0.00 | (m) | $567.00K* | -$22.59M* | (m) | $23.28M | (m) | $0.00 |
| 2022-03-31 | Reported | (m) | -$24.13M | (m) | (m) | (m) | $147.00K | -$1.43M | (m) | $18.08M | (m) | $0.00 |
| 2021-09-30 | Reported | (m) | -$20.20M | (m) | $0.00 | (m) | $145.00K* | -$14.44M* | (m) | $14.83M | (m) | -$38.00K |
| 2021-06-30 | Reported | (m) | -$15.54M | (m) | $100.00K | (m) | $510.00K* | -$17.64M* | (m) | $9.98M | (m) | $0.00 |
| 2021-03-31 | Reported | (m) | -$15.77M | (m) | (m) | (m) | $210.00K | -$10.51M | (m) | $11.49M | (m) | $50.00K |
| 2020-09-30 | Reported | (m) | -$11.95M | (m) | $0.00 | (m) | $30.00K* | -$10.86M* | (m) | $8.39M | (m) | $0.00 |
| 2020-06-30 | Reported | (m) | -$10.91M | (m) | $0.00 | (m) | $28.00K* | -$9.93M* | (m) | $7.26M | (m) | $0.00 |
| 2020-03-31 | Reported | (m) | -$10.50M | (m) | $0.00 | (m) | $176.00K | -$8.12M | (m) | $8.53M | (m) | -$172.00K |
| 2019-09-30 | Reported | (m) | -$2.33M | (m) | $2.50M | (m) | $82.00K* | -$2.96M* | (m) | $3.85M | (m) | $0.00 |
| 2019-06-30 | Reported | (m) | -$2.65M | (m) | $2.50M | (m) | $171.00K* | -$5.03M* | (m) | $4.50M | (m) | $0.00 |
| 2019-03-31 | Reported | (m) | -$2.86M | (m) | $2.50M | (m) | $0.00 | -$2.51M | (m) | $4.87M | (m) | $0.00 |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | $67.57M | (m) | $244.06M | (m) | $1.55M | $107.50M | (m) | $129.64M | (m) | $4.88M |
| 2024-12-31 | Reported | (m) | -$210.83M | (m) | $3.55M | (m) | $1.93M | -$160.87M | (m) | $173.63M | (m) | $300.00K |
| 2023-12-31 | Reported | (m) | -$169.94M | (m) | $151.00K | (m) | $2.46M | -$124.51M | (m) | $135.26M | (m) | $0.00 |
| 2022-12-31 | Reported | (m) | -$114.79M | (m) | $0.00 | (m) | $1.24M | -$70.06M | (m) | $87.27M | (m) | $0.00 |
| 2021-12-31 | Reported | (m) | -$56.37M | (m) | $20.10M | (m) | $1.02M | -$62.15M | (m) | $55.14M | (m) | $2.01M |
| 2020-12-31 | Reported | (m) | -$46.66M | (m) | $0.00 | (m) | $294.00K | -$36.89M | (m) | $33.86M | (m) | -$172.00K |
| 2019-12-31 | Reported | (m) | -$10.56M | (m) | $10.00M | (m) | $271.00K | -$16.00M | (m) | $17.38M | (m) | $0.00 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |